Physician profile
William Chu
NPI 1194875054
$4,442.38
in general payments reported to CMS, 2019-2025
34 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $194 · 2021: $148 · 2022: $48.65 · 2023: $793 · 2024: $1,281 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $813.56 | 2019-2025 | |
| Novo Nordisk INC | $809.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $535.36 | 2019-2025 | Vraylar, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.06 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $160.00 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Cmp Pharma, INC. | $132.40 | 2023-2025 | Atorvaliq, Norliqva, Liqrev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.32 | 2019-2022 | |
| Exact Sciences Corporation | $121.04 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $119.01 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $101.94 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $101.78 | 2019-2020 | |
| Radius Health, INC. | $86.53 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $86.32 | 2019-2025 | |
| Sanofi Pasteur INC. | $84.01 | 2019-2024 | |
| Amgen INC. | $81.64 | 2019-2025 | Repatha, Otezla, Tavneos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $72.78 | 2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $72.08 | 2023-2024 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $58.86 | 2019-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $57.57 | 2019-2024 | Farxiga |
| Idorsia Pharmaceuticals US INC | $57.29 | 2023 | Quviviq |
| Therapeuticsmd, INC. | $53.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $50.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $44.92 | 2019 | |
| Nabriva Therapeutics, Plc | $40.94 | 2020 | |
| Abbott Laboratories | $38.90 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $35.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.85 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $29.60 | 2023 | |
| Sumitomo Pharma America, INC. | $23.21 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $20.37 | 2022 | |
| Amag Pharmaceuticals, INC. | $19.40 | 2019 | |
| Indivior INC. | $17.31 | 2024 | Sublocade |
| Ibsa Pharma INC. | $16.03 | 2023 | Tirosint, Licart |
| Dova Pharmaceuticals | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.